



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/092,954

03/06/2002

David D. Konieczynski

022719-0023

7357

21125

7590

04/29/2004

NUTTER MCCLENNEN & FISH LLP  
WORLD TRADE CENTER WEST  
155 SEAPORT BOULEVARD  
BOSTON, MA 02210-2604

EXAMINER

MAIORINO, ROZ

ART UNIT

PAPER NUMBER

3763

DATE MAILED: 04/29/2004

10

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No.

10/092,954

Applicant(s)

KONIECZYNSKI ET AL.

Examiner

Roz Maiorino

Art Unit

3763

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on 01 March 2004.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 1,3,7,8,10,11,14-17,19,20,22,25 and 28-40 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1,3,7,8,10,11,14-17,19,20,22,25 and 28-40 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

## Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

## Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_\_
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: \_\_\_\_\_

**DETAILED ACTION**

***Claim Rejections - 35 USC § 102***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

1. Claims 1, 3, 10-11, 14-17, 19-20, 22, 28-40 are rejected under 35 U.S.C. 102(e) as being anticipated by US Patent NO.6966218 to Flaherty et al or US Patent NO.

---

6669682 to Gibson et al.

Both Gibson and Flaherty teaches an infusion pump including a fluid outlet; a fluid delivery pathway effective for extending from the fluid outlet to a discharge portion positionable at a target tissue site; and a controlled release drug assembly, the drug assembly being configured for controllably releasing drug material, and communicating with the fluid delivery pathway such that the drug material is released into the fluid delivery pathway, wherein the pump assembly is effective to deliver a carrier fluid to the fluid outlet such that the drug material released into the fluid pathway discharges at the discharge portion to treat the target tissue site. Drug assembly is a microchip; the system also comprises of biosensors. (Figure 1-4 in Gibson and figures 1-2 in Flaherty )

2. Claims 1, 3, 7, 8, 10-11, 14-17, 19-20, 22, 25, 28-40 rejected under 35 U.S.C. 102(b ) as being anticipated by US Patent No. 5989445 to Wise et al.

Wise teaches an infusion pump including a fluid outlet; a fluid delivery pathway effective for extending from the fluid outlet to a discharge portion positionable at a target tissue site; and a controlled release drug assembly, the drug assembly being configured for controllably releasing drug material, and communicating with the fluid delivery pathway such that the drug material is released into the fluid delivery pathway, wherein the pump assembly is effective to deliver a carrier fluid to the fluid outlet such that the drug material released into the fluid pathway discharges at the discharge portion to treat the target tissue site. Drug assembly is a microchip with fluid reservoir, the system also comprises of biosensors. (figure 6)

3. Claims 1, 3, 10-11, 29 are rejected under 35 U.S.C. 102(b) as being anticipated by US Patent NO. 4193397 to Tucker et al.

---

Tucker teaches an infusion pump including a fluid outlet; a fluid delivery pathway effective for extending from the fluid outlet to a discharge portion positionable at a target tissue site; and a controlled release drug assembly, the drug assembly being configured for controllably releasing drug material, and communicating with the fluid delivery pathway such that the drug material is released into the fluid delivery pathway. (figure 2-4)

4. Claims 1, 29-40 are rejected under 35 U.S.C. 102(e) as being anticipated by US patent Pub NO. 2002/0082583 to Lerner.

Lerner teaches an infusion pump for the brain including a fluid outlet; a fluid delivery pathway effective for extending from the fluid outlet to a discharge portion positionable at a target tissue site; and a controlled release drug assembly, the drug assembly being

configured for controllably releasing drug material, and communicating with the fluid delivery pathway such that the drug material is released into the fluid delivery pathway, wherein the pump assembly is effective to deliver a carrier fluid to the fluid outlet such that the drug material released into the fluid pathway discharges at the discharge portion to treat the target tissue site.

***Response to Arguments***

5. Applicant's arguments with respect to claims 1, 3, 7, 8, 10-11, 14-17, 19-20, 22, 25, 28-40 have been considered but are moot in view of the new ground(s) of rejection.

***Conclusion***

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.


Art Unit: 3763

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Roz Maiorino whose telephone number is 703-305-2336. The examiner can normally be reached on 9am-5:30pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brian Casler can be reached on 703-308-3552.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

RM

  
BRIAN L. CASLER  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 3700